Recent News

• 06.11.2025 - Avidity Biosciences to Present Topline Data from Phase 1/2 FORTITUDE™ Trial of Del-brax in People Living with Facioscapulohumeral Muscular Dystrophy at 32nd Annual FSHD Society International Research Congress
• 06.09.2025 - Avidity Biosciences Announces Positive Topline Phase 1/2 FORTITUDE™ Data Demonstrating Consistent Improvement Across Multiple Functional Measures Compared to Placebo in Del-Brax Treated FSHD Participants
• 06.09.2025 - Avidity Biosciences Announces the Accelerated Approval Regulatory Pathway in the U.S. is Open for Del-Brax and Initiates the Global, Confirmatory Phase 3 FORWARD™ Study in FSHD
• 05.21.2025 - Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 05.08.2025 - Avidity Biosciences Reports First Quarter 2025 Financial Results and Recent Highlights
• 05.06.2025 - Avidity Biosciences to Participate in Upcoming Investor Conference

Recent Filings

• 06.11.2025 - 144 Report of proposed sale of securities
• 06.10.2025 - 8-K Current report
• 06.09.2025 - EX-99.1 EX-99.1
• 06.09.2025 - 8-K Current report
• 06.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.02.2025 - 144 Report of proposed sale of securities
• 05.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.12.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.12.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.08.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]